Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
NCT ID NCT07698080
First seen Jul 13, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study tests whether a combination of dexamethasone, intravenous immunoglobulin (IVIG), and extra donor immune cells can safely lower harmful antibodies that attack donor stem cells in half-matched (haploidentical) transplants. The trial enrolls 60 adults aged 18–65 with blood cancers or disorders like leukemia, lymphoma, or aplastic anemia who have these antibodies and no other suitable donor. Participants receive the three treatments just before and during transplant, with the goal of preventing graft failure and improving transplant success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dexamethasone, intravenous immunoglobulin (IVIG), and donor mononuclear cells
- What this could lead to
- If successful, this approach could offer a safer, simpler way to make half-matched stem cell transplants work for patients who have harmful antibodies against their donor.
- What could go wrong
- This is a mid-stage trial with only 60 participants, so results may not apply to everyone. The extra immune cells could increase the risk of graft-versus-host disease, a serious complication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- A pill that mimics the body's oxygen sensor may free MDS patients from frequent blood transfusions
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Could a simple exercise routine strengthen bones in thalassemia?
- Can a drug duo outsmart resistant lymphomas?
- New PET tracer could sharpen diagnosis of blood cancers